REGENXBIO Inc. (RGNX)

REGENXBIO Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	156.72	83.33	90.24	112.72	470.35	154.57
Revenue	156.72	83.33	90.24	112.72	470.35	154.57
Revenue Growth (YoY)	80.70%	-7.66%	-19.94%	-76.03%	204.30%	338.70%
Cost of Revenue	30.96	33.57	37.21	54.55	233.27	202.01
Gross Profit	125.76	49.76	53.03	58.18	237.08	-47.44
Selling, General & Admin	78.68	76.62	87.79	85.28	79.33	63.82
Research & Development	208.52	208.52	229.27	242.45	-	-
Other Operating Expenses	0.91	0.87	0.4	-14.18	0.33	0.3
Operating Expenses	283.11	281.01	317.46	313.56	77.1	71.79
Operating Income	-157.36	-231.25	-264.43	-255.38	159.98	-119.23
Interest Expense	-19.26	-12.66	-6.86	-23.25	-26.28	-0.77
Interest & Investment Income	18.92	18.9	11.34	5.73	7.54	13.99
EBT Excluding Unusual Items	-157.69	-225	-259.95	-272.91	141.25	-106.01
Merger & Restructuring Charges	-	-	-3.7	-	-	-
Asset Writedown	-	-2.1	-	-	-	-
Other Unusual Items	-	-	-	-7.5	-	-
Pretax Income	-157.69	-227.1	-263.65	-280.41	141.25	-106.01
Income Tax Expense	-	-	-0.15	-0.08	13.41	5.24
Net Income	-157.69	-227.1	-263.49	-280.32	127.84	-111.25
Net Income to Common	-157.69	-227.1	-263.49	-280.32	127.84	-111.25
Shares Outstanding (Basic)	51	50	44	43	42	37
Shares Outstanding (Diluted)	51	50	44	43	44	37
Shares Change (YoY)	14.92%	13.21%	1.35%	-1.73%	17.79%	1.61%
EPS (Basic)	-3.10	-4.59	-6.02	-6.50	3.01	-2.98
EPS (Diluted)	-3.10	-4.59	-6.02	-6.50	2.91	-2.98
Free Cash Flow	-86.94	-175.56	-228.37	-238.21	134.7	-80.93
Free Cash Flow Per Share	-1.71	-3.55	-5.22	-5.52	3.07	-2.17
Gross Margin	80.24%	59.72%	58.76%	51.61%	50.41%	-30.69%
Operating Margin	-100.41%	-277.51%	-293.02%	-226.55%	34.01%	-77.14%
Profit Margin	-100.62%	-272.54%	-291.99%	-248.68%	27.18%	-71.97%
Free Cash Flow Margin	-55.48%	-210.69%	-253.06%	-211.32%	28.64%	-52.36%
EBITDA	-141.37	-215.03	-247.11	-242.47	169.54	-110.83
EBITDA Margin	-90.20%	-258.05%	-273.83%	-215.10%	36.05%	-71.70%
D&A For EBITDA	15.99	16.22	17.32	12.91	9.56	8.41
EBIT	-157.36	-231.25	-264.43	-255.38	159.98	-119.23
EBIT Margin	-100.41%	-277.51%	-293.02%	-226.55%	34.01%	-77.14%
Effective Tax Rate	-	-	-	-	9.49%	-
Revenue as Reported	156.72	83.33	90.24	112.72	470.35	154.57

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q